Bejelentkezés Regisztrálj ingyen

Last updated: 15 July 2022 at 5:10pm EST

Joshua Bilenker Net Worth



Joshua Bilenker GOSS stock SEC Form 4 insiders trading

Joshua has made over 17 trades of the Gossamer Bio stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 20,000 units of GOSS stock worth $273,400 on 10 December 2018.

The largest trade he's ever made was selling 57,000 units of Gossamer Bio stock on 19 June 2018 worth over $10,181,340. On average, Joshua trades about 11,700 units every 16 days since 2015. As of 10 December 2018 he still owns at least 174,407 units of Gossamer Bio stock.

You can see the complete history of Joshua Bilenker stock trades at the bottom of the page.





Joshua Bilenker biography

Dr. Joshua H. Bilenker M.D. serves as Independent Director of the Company. He has served as Chief Executive Officer of Loxo Oncology, Inc. since July 2013. Dr. Bilenker joined Aisling Capital LLC in April 2006 and has served as an Operating Partner since November 2013. Previously, Dr. Bilenker served as a Medical Officer in the Office of Oncology Drug Products at the FDA from August 2004 to April 2006. Dr. Bilenker has served on the board of directors of Loxo Oncology, Inc. since July 2013 as well as on the boards of directors of several private companies. Dr. Bilenker previously served on the board of directors of ViewRay, Inc. from January 2008 to June 2017, T2 Biosystems, Inc. from August 2011 to January 2017 and Roka Bioscience, Inc. from January 2012 to March 2015. Dr. Bilenker formerly served as a board member of the NCCN Foundation and BioEnterprise. Dr. Bilenker holds an A.B. in English from Princeton University and an M.D. from the Johns Hopkins School of Medicine.

What is the salary of Joshua Bilenker?

As the Independent Director of Gossamer Bio, the total compensation of Joshua Bilenker at Gossamer Bio is $334,937. There are 11 executives at Gossamer Bio getting paid more, with Jakob Dupont having the highest compensation of $3,530,450.



How old is Joshua Bilenker?

Joshua Bilenker is 48, he's been the Independent Director of Gossamer Bio since 2018. There are 12 older and 3 younger executives at Gossamer Bio. The oldest executive at Gossamer Bio, Inc. is Thomas Daniel, 66, who is the Independent Director.

What's Joshua Bilenker's mailing address?

Joshua's mailing address filed with the SEC is 3013, Science Park Road, Torrey Pines, San Diego, San Diego County, California, 92121, United States.

Insiders trading at Gossamer Bio

Over the last 6 years, insiders at Gossamer Bio have traded over $10,765,709 worth of Gossamer Bio stock and bought 2,039,396 units worth $4,494,757 . The most active insiders traders include Kristina Burow, Faheem Hasnain és Fund V, L.P.Omega Fund V Gp.... On average, Gossamer Bio executives and independent directors trade stock every 33 days with the average trade being worth of $40,853. The most recent stock trade was executed by Richard Aranda on 24 June 2024, trading 1,908 units of GOSS stock currently worth $1,259.



What does Gossamer Bio do?

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.



What does Gossamer Bio's logo look like?

Gossamer Bio, Inc. logo

Gossamer Bio executives and stock owners

Gossamer Bio executives and other stock owners filed with the SEC include: